X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The acquisition supplements BioVaxys' existing cancer vaccine portfolio with the addition of DPX-Survivac (maveropepimut-S), a DPX™-formulated cancer vaccine that delivers antigenic peptides from survivin, a cancer antigen commonly overexpressed in advanced cancers.
Lead Product(s): Maveropepimut-S,Pembrolizumab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: DPX-Survivac
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Biovaxys
Deal Size: $25.7 million Upfront Cash: $25.7 million
Deal Type: Acquisition February 12, 2024
Details:
IMV’s lead candidate, DPX-Survivac (maveropepimut-S), delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers.
Lead Product(s): Maveropepimut-S,Pembrolizumab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: DPX-Survivac
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
IMV’s lead candidate, DPX-Survivac (maveropepimut-S), delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers.
Lead Product(s): Maveropepimut-S,Pembrolizumab
Therapeutic Area: Oncology Product Name: DPX-Survivac
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2023
Details:
DPX-Survivac (maveropepimut-S) is a novel T cell immunotherapy that uses the DPX platform to elicit strong and sustained survivin-specific T cell responses against tumor cells.
Lead Product(s): Maveropepimut-S,Pembrolizumab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: DPX-Survivac
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 20, 2022
Details:
DPX-Survivac (maveropepimut-S) is a novel T cell immunotherapy that uses the DPX platform to elicit strong and sustained survivin-specific T cell responses against tumor cells.
Lead Product(s): Maveropepimut-S,Pembrolizumab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: DPX-Survivac
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 16, 2022
Details:
IMV’s lead candidate, DPX-Survivac (maveropepimut-S, MVP-S), delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers.
Lead Product(s): Maveropepimut-S,Pembrolizumab
Therapeutic Area: Oncology Product Name: DPX-Survivac
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
Maveropepimut-S (DPX-Survivac) Generating Cancer-Targeted Killer T Cells combines advantages of DPX platform and cancer antigen survivin, is lead candidate of IMV’s new class of immunotherapies that generates cancer-targeted T cells in vivo.
Lead Product(s): Maveropepimut-S,Cyclophosphamide
Therapeutic Area: Oncology Product Name: DPX-Survivac
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
Combination of DPX-Survivac (maveropepimut-s) and pembrolizumab showed encouraging clinical activity in advanced, metastatic bladder cancer patients, particularly in patients who had received prior immune checkpoint inhibitor therapy.
Lead Product(s): Maveropepimut-S,Pembrolizumab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: DPX-Survivac
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
DPX-Survivac, a novel T cell immunotherapy that uses the DPX platform to elicit a coordinated anti-tumor immune response involving natural killer cells in both translational and preclinical studies.
Lead Product(s): Maveropepimut-S,Cyclophosphamide
Therapeutic Area: Oncology Product Name: DPX-Survivac
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
